Provided is a method for producing a cell contained base, the method being capable of providing a cell contained base highly accurately controlled in number of nucleic acid molecules contained in a low-concentration nucleic acid standard sample, the method including a liquid droplet discharging step of discharging a cell suspension in the form of a liquid droplet with a liquid droplet discharging unit onto a base including at least one cell contained region; a cell number counting step of counting a number of cells contained in the liquid droplet with a plurality of sensors from two or more directions while the liquid droplet is flying into the cell contained region; and a liquid droplet landing step of landing the liquid droplet in the at least one cell contained region in a manner that a predetermined number of cells are located in the at least one cell contained region.

Methods of detecting and quantifying target molecules, such as proteins, in a biological sample are provided. The disclosed methods include capturing target molecules with aptamers, replacing the aptamers with aptamer identification sequences, and then sequencing the aptamer identification sequences using next-generation sequencing techniques.

Methods of detecting and quantifying target molecules, such as proteins, in a biological sample are provided. The disclosed methods include capturing target molecules with aptamers, replacing the aptamers with aptamer identification sequences, and then sequencing the aptamer identification sequences using next-generation sequencing techniques.

This invention relates to methods and compositions for assessing an amount of donor-specific fraction of cell-free DNA, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant organ injury (e.g., cellular injury), cellular rejection grade, antibody-mediated rejection, cardiac allograft vasculopathy, and/or cardiac arrest in a transplant subject.

This invention relates to methods and compositions for assessing an amount of donor-specific fraction of cell-free DNA, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant organ injury (e.g., cellular injury), cellular rejection grade, antibody-mediated rejection, cardiac allograft vasculopathy, and/or cardiac arrest in a transplant subject.

It is an object of the present disclosure to provide a method for reducing the influence of baseline disturbances in a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR using a fluorescent dye, with a simple method. The present disclosure provides a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR, the method including: (1) amplifying the target nucleic acid in the dry blood filter paper by applying thermal cycles to a sample solution containing a dry blood filter paper punch piece and a PCR reagent, wherein the PCR reagent includes a fluorescently labeled probe; (2) optically detecting the fluorescence intensity of the sample solution for each of the thermal cycles; and (3) performing quantitative analysis of the target nucleic acid using data after a predetermined number of cycles of the optically detected data.

It is an object of the present disclosure to provide a method for reducing the influence of baseline disturbances in a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR using a fluorescent dye, with a simple method. The present disclosure provides a method for detecting a target nucleic acid in dry blood filter paper by real-time PCR, the method including: (1) amplifying the target nucleic acid in the dry blood filter paper by applying thermal cycles to a sample solution containing a dry blood filter paper punch piece and a PCR reagent, wherein the PCR reagent includes a fluorescently labeled probe; (2) optically detecting the fluorescence intensity of the sample solution for each of the thermal cycles; and (3) performing quantitative analysis of the target nucleic acid using data after a predetermined number of cycles of the optically detected data.

Provided herein are a set of primers and probes for detecting rotavirus. The set of primers and probes includes at least one forward primer selected from the group including SEQ ID NOS: 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104, 107, 110, 113, 116, 119, 122, 125, 128, 131, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 204, 207, 210, and combinations thereof; at least one reverse primer selected from the group including SEQ ID NOS: 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 205, 208, 211, and combinations thereof; and at least one probe selected from the group including SEQ ID NOS: 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 206, 209, 212, and combinations thereof. Also provided herein is a method for detecting rotavirus using the set of primers and probes.

Provided herein are a set of primers and probes for detecting rotavirus. The set of primers and probes includes at least one forward primer selected from the group including SEQ ID NOS: 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104, 107, 110, 113, 116, 119, 122, 125, 128, 131, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 204, 207, 210, and combinations thereof; at least one reverse primer selected from the group including SEQ ID NOS: 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 120, 123, 126, 129, 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 205, 208, 211, and combinations thereof; and at least one probe selected from the group including SEQ ID NOS: 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 115, 118, 121, 124, 127, 130, 133, 136, 139, 142, 145, 148, 151, 154, 157, 160, 163, 166, 169, 206, 209, 212, and combinations thereof. Also provided herein is a method for detecting rotavirus using the set of primers and probes.

Provided is a method for evaluating the viral clearance capability of a virus removal medium, comprising the steps of: (a) adding a viral capsid-containing liquid to a solution to be purified; (b) contacting the virus removal medium with the solution to be purified that has been supplemented with the viral capsid-containing liquid to harvest a purified solution; and (c) quantifying a total viral capsid in the solution to be purified before the purification and a total viral capsid in the purified solution.